We are live on ! Find out more
Pacer Advisors

Pacer Advisors Portfolio holdings

AUM $35.6B
1-Year Est. Return 18.19%
This Fund
S&P 500
This Quarter Est. Return
+7.06%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$2.66B
AUM Growth
+$447M
Cap. Flow
+$395M
Cap. Flow %
14.87%
Top 10 Hldgs %
18.05%
Holding
1,302
New
172
Increased
969
Reduced
51
Closed
109

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$18.9M
2
MSFT icon
Microsoft
MSFT
+$13.5M
3
AAPL icon
Apple
AAPL
+$12.1M
4
XOM icon
ExxonMobil
XOM
+$7.45M
5
META icon
Meta Platforms (Facebook)
META
+$7.29M

Sector Composition

Rank Sector Weight
1 Technology 21.37%
2 Healthcare 13.73%
3 Consumer Discretionary 11.89%
4 Financials 11.87%
5 Industrials 9.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMMU
1001
DELISTED
Immunomedics Inc
IMMU
$228K 0.01%
+10,967
New +$260K
RGNX icon
1002
Regenxbio
RGNX
$623M
$227K 0.01%
+3,011
New +$217K
ESPR
1003
DELISTED
Esperion Therapeutics
ESPR
$226K 0.01%
+5,090
New +$234K
LZB icon
1004
La-Z-Boy
LZB
$1.59B
$226K 0.01%
7,161
+4,211
+143% +$134K
CLVS
1005
DELISTED
Clovis Oncology, Inc.
CLVS
$226K 0.01%
+7,688
New +$298K
ARWR icon
1006
Arrowhead Research
ARWR
$12.1B
$224K 0.01%
+11,704
New +$192K
HRTX icon
1007
Heron Therapeutics
HRTX
$86.3M
$223K 0.01%
+7,053
New +$263K
ONCE
1008
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$223K 0.01%
+4,092
New +$280K
RARE icon
1009
Ultragenyx Pharmaceutical
RARE
$2.65B
$222K 0.01%
+2,910
New +$237K
UA icon
1010
Under Armour Class C
UA
$2.92B
$222K 0.01%
11,421
+2,739
+32% +$52.9K
NCI
1011
DELISTED
Navigant Consulting, Inc.
NCI
$222K 0.01%
+9,642
New +$223K
GBT
1012
DELISTED
Global Blood Therapeutics, Inc.
GBT
$221K 0.01%
+5,807
New +$257K
PTLA
1013
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$221K 0.01%
+8,315
New +$271K
CCOI icon
1014
Cogent Communications
CCOI
$594M
$218K 0.01%
+3,905
New +$209K
PRGS icon
1015
Progress Software
PRGS
$1.55B
$218K 0.01%
6,188
+4,047
+189% +$161K
TVTY
1016
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$217K 0.01%
6,759
+3,981
+143% +$136K
NTLA icon
1017
Intellia Therapeutics
NTLA
$1.5B
$216K 0.01%
+7,558
New +$220K
ATRA icon
1018
Atara Biotherapeutics
ATRA
$71.2M
$215K 0.01%
+208
New +$203K
HIBB
1019
DELISTED
Hibbett, Inc. Common Stock
HIBB
$215K 0.01%
11,451
+8,438
+280% +$191K
AVTA
1020
DELISTED
Avantax, Inc. Common Stock
AVTA
$214K 0.01%
+5,308
New +$193K
IMGN
1021
DELISTED
Immunogen Inc
IMGN
$213K 0.01%
+22,520
New +$216K
EBS icon
1022
Emergent Biosolutions
EBS
$375M
$205K 0.01%
+3,113
New +$182K
CROX icon
1023
Crocs
CROX
$6.69B
$203K 0.01%
9,556
+5,463
+133% +$105K
EGHT icon
1024
8x8 Inc
EGHT
$247M
$202K 0.01%
+9,498
New +$207K
SPPI
1025
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$202K 0.01%
+11,999
New +$260K

Similar funds

Pacer Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Pacer Advisors held 1,302 positions worth $2.66B, up 20% from $2.21B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Pacer Advisors deployed $395M of net new capital in Q3 2018, opening 172 new positions and adding to 969 existing holdings. Its largest new stake was VMware, Inc: 19,828 shares worth $3.09M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $3.26M trimmed.

  • Pacer Advisors's largest Q3 2018 buy was VMware, Inc: 19,828 shares worth $3.09M.
  • Pacer Advisors added most to Amazon in Q3 2018, an estimated $18.9M increase.
  • Pacer Advisors's biggest Q3 2018 reduction was Wellcare Health Plans, Inc., cutting an estimated $3.26M.
  • Pacer Advisors fully exited BASF AKTIENGESELLT ADS(RP1 ORD in Q3 2018, selling an estimated $7.2M.
  • Pacer Advisors's ten largest holdings make up 18% of its $2.66B portfolio in Q3 2018.
  • Pacer Advisors opened 172 new positions and closed 109 in Q3 2018.
  • Pacer Advisors's portfolio value rose 20% quarter-over-quarter to $2.66B.

Based on Pacer Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.